Turner et al. [1] raise an important and timely issue about the management of CF patients suffering chronic infection with methicillin-resistant Staphylococcus aureus (MRSA), given that the prevalence of MRSA in respiratory cultures of CF patients has increased over the past decade. In our study [2], the prevalence of chronic MRSA colonization in the CF Center of the University Hospital of Brussels was 12.6%. Our spirometric data showed that a MRSA episode entailed an FEV1 decline that was almost double that predicted for CF patients who could remain unaffected by MRSA.